Zacks Research Downgrades Aytu BioPharma (NASDAQ:AYTU) to Strong Sell

Aytu BioPharma (NASDAQ:AYTU) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Wednesday,Zacks.com reports.

A number of other equities analysts have also commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Ascendiant Capital Markets boosted their price objective on Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.75.

Aytu BioPharma Stock Performance

NASDAQ:AYTU opened at $2.16 on Wednesday. Aytu BioPharma has a 1 year low of $1.65 and a 1 year high of $3.07. The firm’s fifty day simple moving average is $2.20 and its 200 day simple moving average is $2.44. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $23.18 million, a PE ratio of -0.47 and a beta of 0.24.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.09). The firm had revenue of $12.41 million during the quarter, compared to the consensus estimate of $12.05 million. Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%. On average, sell-side analysts anticipate that Aytu BioPharma will post -0.73 EPS for the current year.

Institutional Investors Weigh In On Aytu BioPharma

Several hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP acquired a new stake in Aytu BioPharma during the third quarter worth about $58,000. Two Sigma Investments LP raised its holdings in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after acquiring an additional 33,701 shares in the last quarter. FNY Investment Advisers LLC raised its holdings in Aytu BioPharma by 24,207.7% in the 4th quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock valued at $82,000 after acquiring an additional 31,470 shares in the last quarter. Daytona Street Capital LLC acquired a new position in Aytu BioPharma in the 4th quarter valued at approximately $26,000. Finally, Bellevue Asset Management LLC bought a new stake in shares of Aytu BioPharma in the 4th quarter worth approximately $65,000. Institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.